AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06243419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vein viewer and virtual reality
Description: The PIC region was visualized with the help of the device, and the vein to which the intervention would be applied was determined.~The child watched the application by wearing virtual glasses during the PIC insertion
Study NCT05566314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amunizer
Description: 12 oz. herbal, probiotic and antioxidant herbal beverage
Study NCT05566314 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 oz. flavored beverage
Study NCT06655818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin
Description: Belantamab Mafodotin will be administered.
Study NCT06655818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.
Study NCT06654154 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: variation of serum level vitamine B12
Description: There will be no specific visit to the study. Follow-up in consultation will be done by your referring doctor. A determination of the serum level of vitamin B12 will be carried out at inclusion, during a consultation where the pathology is in remission (during the classic assessment of follow-up under tocilizumab, left to the discretion of the patient's referring doctor. ). It will also be necessary to carry out, in addition to the classic assessment left to the discretion of the patient's doctor, a determination of the serum level of vitamin B12 in the event of clinical suspicion of infection or an outbreak of MAI/I.~The determination of serum vitamin B12 requires the collection of an additional tube of 300 μl of venous blood but no additional venipuncture
Study NCT05263479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20089 (Phase Ia：Dose escalation )
Description: Participants will receive HS-20089 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
Study NCT06589076 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical and Radiographic assessment + Questionnaires
Description: * Clinical and radiographic examination to assess oral health and apical periodontitis.~* Questionnaires to assess Anxiety and depression.
Study NCT06590766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure/relaxation with acupuncture
Description: The acupressure/acupuncture points will be designated according to a protocol for each of the four leading concerns (pain, fatigue, emotional, and gastrointestinal), based on evidence-based research. For example, clinical guideline-based IO protocols for pain relief will include the following analgesia-related acupressure/acupuncture points: Liver-3, Taichong; Large-Intestine 4, Hegu; Stomach-36, Zusanli; Pericard-6, Neiguan; Spleen-6, Sanyinjiao; Yin tang; as well as battlefield ear acupuncture points. In both IO intervention groups, relaxation techniques will be tailored to the patient's main concern, with the option of including breathing and guided imagery modalities as well.
Study NCT05263479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20089 (Phase Ib: Dose expansion)
Description: IV administration of HS-20089 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
Study NCT06590766 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupressure/relaxation with acupuncture
Description: The acupressure/acupuncture points will be designated according to a protocol for each of the four leading concerns (pain, fatigue, emotional, and gastrointestinal), based on evidence-based research. For example, clinical guideline-based IO protocols for pain relief will include the following analgesia-related acupressure/acupuncture points: Liver-3, Taichong; Large-Intestine 4, Hegu; Stomach-36, Zusanli; Pericard-6, Neiguan; Spleen-6, Sanyinjiao; Yin tang; as well as battlefield ear acupuncture points. In both IO intervention groups, relaxation techniques will be tailored to the patient's main concern, with the option of including breathing and guided imagery modalities as well.
Study NCT06599853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fever Education
Description: Another aspect of this research that is different from other studies is that a retention test will be applied to the participants after the pre-test and post-test, and the long-term effect of the training given will be examined. In this direction, it is aimed to reduce the inappropriate use of emergency services, the use of unnecessary tests and the increasing health system costs. It is aimed to prevent crowding in the emergency department by reducing the inappropriate use of emergency services.
Study NCT06591221 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chuna Maintenance Therapy
Description: it is conducted every two weeks for a total of 20 weeks for individuals. The technique follows the guidelines of the Society of Chuna Manual Medicine and is based on Chuna Medicine (2.5th edition), which is utilized as a textbook in Korean Medicine colleges.~The treatment is selectively administered based on the clinical judgment of the practitioner.
Study NCT06591221 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chuna Maintenance Therapy
Description: it is conducted every two weeks for a total of 20 weeks for individuals. The technique follows the guidelines of the Society of Chuna Manual Medicine and is based on Chuna Medicine (2.5th edition), which is utilized as a textbook in Korean Medicine colleges.~The treatment is selectively administered based on the clinical judgment of the practitioner.
Study NCT06595394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants in the experimental group will receive treatment for 8 weeks, 3 sessions per week. Each treatment session will be planned to last 60 minutes. People in the experimental group will receive a combined exercise training consisting of aerobic exercise, balance exercise and strengthening exercises for 8 weeks.
Study NCT06595394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home program
Description: The control group will be followed with a home program for 8 weeks. Patients will be asked to apply the home program, which includes traditional physiotherapy practices, 3 days a week and this will be followed by physiotherapists.
Study NCT06590259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-mode tumor treatment system
Description: All subjects are treated using the multi-mode tumor treatment system (Shanghai MAaGI Medical Technology Co., Ltd), with the treatment procedure conducted according to the temperature control mode for tumor ablation. Complete ablation of intrahepatic lesions is achieved to realize an intrahepatic no-evidence-of-disease (NED) state. For lesions that could not be ablated in a single session, two treatments are performed to achieve NED within the liver.
Study NCT06590259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab+mFOLFOX6 or FOLFIRI+bevacizumab or cetuximab
Description: Systemic therapy including PD-1 inhibitor starts on the 7th day after ablation (sintilimab 200 mg IV D1 + mFOLFOX6 or FOLFIRI + bevacizumab or cetuximab (determined according to the subject's first-line chemotherapy regimen), Q3W, chemotherapy for 4-6 cycles. Sintilimab continues until disease progression, not exceeding a maximum of 2 years.）
Study NCT06313307 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: topical H2R antagonist
Description: Topical H2RA (2% famotidine solution solved in double-distilled water (containing poloxamer 407, glycerol, lauryl alcohol polyether-4, polyethylene glycol-8, and propylene glycol)) was applied topically twice per day in the morning and the evening for 16 weeks.
Study NCT06313307 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thulium 1927-nm Fractional Laser
Description: 1927nm fractional laser (South Korea, WONTECH, Lavieen) was performed with 4-week interval (Week 0, 4, 8, 12 and 16) for a total of 4 treatments. The parameter of 1927nm fractional laser was as follows: duration 600-800um, 10w, density 0.8mm, 1 pass.
Study NCT06313307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thulium 1927-nm Fractional Laser
Description: 1927nm fractional laser (South Korea, WONTECH, Lavieen) was performed with 4-week interval (Week 0, 4, 8, 12 and 16) for a total of 4 treatments. The parameter of 1927nm fractional laser was as follows: duration 600-800um, 10w, density 0.8mm, 1 pass.
Study NCT06655259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TURP
Description: Participants will undergo Transurethral Resection of the Prostate (TURP), a surgical procedure performed to relieve symptoms of urinary obstruction caused by the prostate tumor
Study NCT06655259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Description: Participants will receive Standard Medical Therapy, which includes ADT, typically with an LHRH agonist or antagonist, to reduce testosterone levels, a key driver of prostate cancer progression. In addition to ADT, participants may be treated with second-generation anti-androgen drugs such as Abiraterone or Enzalutamide. These medications block androgen receptor signaling and further inhibit the cancer\&#39;s ability to grow.
Study NCT06655571 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound guided caudal Block
Description: caudal block using Ultrasound
Study NCT06655571 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventionel
Description: Caudal Block based on anatomical landmarks
Study NCT06595862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EA-Avatar
Description: The avatar-guided digital intervention includes monitoring of alcohol use and common triggers suicidal thoughts, skills to manage alcohol use and suicidal thoughts, resources on how to access outpatient care and crisis hotlines for suicidal thoughts, and achievements for milestones. In addition, text messages provide reminders to access the avatar platform to learn or practice skills and provide encouragement.
Study NCT04811209 — intervention group
Intervention type: OTHER
Intervention: 1.Baseline Measurements Before Surgery
Description: * Baseline demographic data~* Baseline physiological variables (blood pressure, heart rate, respiratory rate, oxygen saturation)~* Baseline investigations (hemoglobin, coagulation profile, serum electrolytes) if appropriate.~* Preoperative pain state using NRS (0-10)~* Preoperative functional state using the QoR-15 questionnaire~* Pain expectation - patients will be asked preoperatively with the question In a scale from 0 to 10 (where 0 = no pain and 10 = worst pain imaginable), what do you consider is an acceptable pain score for your first (and second) day after surgery?... Two weeks after surgery?~* Pain castastrophizing scale
Study NCT04811209 — intervention group
Intervention type: OTHER
Intervention: 2.Intraoperative Anesthetic Management
Description: All study patients will be managed per routine clinical practice and institutional standard for the performed surgery.
Study NCT04811209 — intervention group
Intervention type: OTHER
Intervention: 3.Postoperative Analgesic Management
Description: postoperative pain will be managed on the ward using a multimodal analgesic regimen as appropriate. This includes:~1. acetaminophen 650 - 1,000 mg given orally every 6 hours around the clock~2. NSAIDs e.g., celecoxib or other agents given orally around the clock per clinical guideline; omit if contraindicated or per surgeon's preference~3. Opioids e.g., hydromorphone 1-2 mg or oxycodone 15-30 mg given orally every 1-2 hours as required by the patient per standard nurse administered analgesic protocol.~4. In the event of severe pain refractory to the above treatments, the patient will be offered IV opioid e.g., intermittent doses of 0.2-0.4 mg hydromorphone IV every 10 minutes until pain becomes tolerable
Study NCT04811209 — intervention group
Intervention type: OTHER
Intervention: 4.Postoperative NRS Pain Assessment
Description: Pain assessment using NRS pain scores (0 = no pain and 10 = worst possible pain) will be performed by an independent research staff, starting immediately in the PACU and serially over the first 48 hours after surgery or until hospital discharge.
Study NCT04811209 — intervention group
Intervention type: OTHER
Intervention: 5.Postoperative Global Rating Scale (GRS) Pain Assessment
Description: Also, the degree of pain relief after treatment is assessed using a subjective 15-point Global Rating Scale (GRS) as mentioned above (Background). This is performed at the same time of each NRS assessment and a minimum of twice daily
Study NCT04811209 — intervention group
Intervention type: OTHER
Intervention: 6.Postoperative Patient Acceptable Symptom State (PASS) Assessment for Pain
Description: During each NRS pain assessment before or after an analgesic intervention on POD 0, 1 and 2, the patient will also be asked this question- In your opinion, do you consider your current pain state satisfactory after your operation? Patients giving a positive response are considered having an acceptable pain state. The PASS is the 75th centile for the pain NRS score in those with a satisfactory pain state.
Study NCT04811209 — intervention group
Intervention type: OTHER
Intervention: 7.Postoperative Quality of Recovery Assessment
Description: The quality of recovery 15 questionnaire (QoR-15) to measure the dimension of quality of recovery will be administered once in the morning of POD 1 and POD 2. The MCID and PASS for QoR are determined in the same way as for NRS score. The final MCID value will be average of 4 values, 1 generated by the anchor based method and 3 generated by the distribution based method. The PASS for QoR is the 75th centile of the QoR-15 score in those patients who rated their recovery as good.
Study NCT04811209 — intervention group
Intervention type: OTHER
Intervention: 8.Other Postoperative Assessments
Description: Additionally, opioid related adverse effects e.g., nausea, vomiting, itchiness, constipation, sedation (RASS + Ramsay)/ and respiratory depression will be assessed daily.
Study NCT04938024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C is a commercially available over-the-counter food supplement.
Study NCT04938024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Vitamin C is a commercially available over-the-counter food supplement.
Study NCT05617352 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Since the data were collected retrospectively, there were no interventions
Description: Since the data were collected retrospectively, there were no interventions
Study NCT04844801 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Risk control strategy
Description: * Magnesium sulfate 2g intravenous bolus over 20 mn (if creatinine clearance >30 mL/min)~* Control of the modifiable NOSVA risk factors: hypovolemia, sepsis, metabolic disorders (e.g., hypokalemia, hyponatremia), acidosis, hypoxia, excess cardiac inotropism of vasopressors, central venous catheter malposition, hyperthermia.
Study NCT04844801 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rate control strategy:
Description: * Risk-control as described above~* Low dose amiodarone:~  * Intravenous bolus (day-1): 4 mg/kg over 1hr (maximum 300 mg i.e. 2 IVL vials over 1 hour )~ * Enteral dose maintenance (day-1 to day-7): 200mg once a day (150 mg intravenous over 1hr if enteral route is unavailable)
Study NCT04844801 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rhythm control strategy:
Description: * Risk control as described above~* High dose amiodarone:~  * Intravenous bolus (day-1): 7 mg/kg over 1hr 1 hour (maximum 600 mg i.e. 4 IVL vials over 1 hour); followed by continuous intravenous maintenance: for a total of 1200 mg over the first 24 hrs (infusion pump)~ * Enteral dose maintenance Day-2 and day-3: 400 mg three times a day (720 mg continuous intravenous over 24 hrs if enteral route is unavailable).~Day-4 to day-7: 200 mg once a day (150 mg intravenous over 1hr if enteral route is unavailable)~- Electrical cardioversion (only in patients intubated on mechanical ventilation) if:~* NOSVA persists after initial bolus of amiodarone AND norepinephrine base (or epinephrine base) doses > 0.3 µg/kg/min;~* NOSVA persists more than 6 hrs after initial amiodarone bolus.
Study NCT05830409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multisensorial Stimulation
Description: Strategies such as touching, calling, making sense of smell, entering the eye area, and activating the sense of taste will be applied to activate the five senses of the newborn.
Study NCT06078839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate
Description: Nafamostat mesilate treatment group was dissolved with 5% glucose at the dosage of 2.0mg/kg/ day to a total of 50ml(Maximum concentration 10mg/ml)
Study NCT06078839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% glucose
Description: Add 50ml of 5% glucose into a 50ml syringe
Study NCT04760054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HUBOD
Description: Participants in the intervention group will attend 5 separate training sessions instructing them in Hubod. The Hubod exercise is a partnered coordination drill involving moves derived from numerous martial arts, most often seen in the Filipino martial art of Kali. Participants will aim to reach a level of comfort and competency in the basic, non-competitive aspects of the Hubod exercise by the end of their participation in this intervention.
Study NCT04760054 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Participants in the active comparator group will attend 5 separate training sessions. Each session will involve a 5 minute warmup of joint mobilization exercises and mild pedaling on the bicycle before the main effort of continuously using the bicycle for approximately 20 minutes. The session finishes with a 5 minute cooldown period and light stretch. Heartrate will be monitored regularly in order to prevent this exercise exceeding the relative intensity of the Martial Arts intervention group. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
Study NCT04760054 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Condition
Description: Participants in this group will attend 5 separate training sessions. Each session will involve watching educational videos on martial arts techniques and training methods from a sedentary position. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
Study NCT06598176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colli-Pee 20mL device with UCM
Description: Women will collect a first-void urine (the initial part of the urine stream) sample at home the day before a hospital appointment using the 20mL Colli-Pee device prefilled with urine conservation medium (UCM, Novosanis, Belgium).
Study NCT06598176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evalyn Brush
Description: Women will collect a vaginal self-sample using the Evalyn Brush (Rovers Medical Devices, The Netherlands) at home the day before a hospital appointment.
Study NCT06592066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Impression by using Intraoral Scanning of Scan Bodies
Description: intraoral scanning will be used to capture the positions of full-arch mandibular implants with the aid of scan bodies.
Study NCT06592066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Impression by using Intraoral Scanning of Scan Bodies with Prefabricated Landmarks
Description: intraoral scanning will be used to capture the positions of full-arch mandibular implants with the aid of scan bodies with prefabricated landmarks in place.
Study NCT06592066 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splinted Open Top Tay Conventional Impression Technique
Description: Splinted open-top tray conventional impression technique will be preformed by using medium body silicone impression material.
Study NCT06591416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: minimally invasive surgical technique
Description: minimally invasive surgical technique
Study NCT06591416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive surgical technique with granulation tissue preservation
Description: minimally invasive surgical technique with granulation tissue preservation
Study NCT06586177 — intervention group
Intervention type: DRUG
Intervention: Anti-CD20 antibody
Description: Study participants receive an anti-CD20 antibody according to the summary of product characteristics.
Study NCT06053671 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood and nasal swab sampling
Description: Genetic screening of DNA samples (blood, mucosal swab, brain tissue) from 60-100 patients with histologically confirmed diagnosis of FCDIIA/B identified from Epilepsy Surgery Databases.
Study NCT06587087 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartest-AE: The lancet that will be used will be the Vitrex Soft Lite lll 28G.
Description: The lancet that will be used for all subjects will be the Vitrex Soft Lite lll 28G.
Study NCT06587087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartest-AE: The lancet that will be used will be the Vitrex Soft Lite lll 28G.
Description: The lancet that will be used for all subjects will be the Vitrex Soft Lite lll 28G.
Study NCT06600256 — intervention group
Intervention type: BEHAVIORAL
Intervention: Viz HCM ECG Review
Description: Viz HCM will auto-alert relevant users to ECGs the algorithm has deemed as suspicious for HCM. Following review of this alert and the patient\&amp;#39;s Medical/Clinical History, the reviewer will take the next Standard of Care action they deem appropriate.
Study NCT06600256 — intervention group
Intervention type: BEHAVIORAL
Intervention: Baseline Effectiveness Cohort
Description: A review of the timing and clinical details of the diagnostic process for patients diagnosed with HCM before the site began using Viz HCM.